Item 2.02 Results of Operations and Financial Condition

As of December 31, 2020, G1Therapeutics, Inc.'s (the "Company") cash, cash equivalents and investments balance was approximately $207 million.

Item 7.01 Regulation FD Disclosure

Attached to this Current Report on Form 8-K as Exhibit 99.1 is a presentation (the "Presentation"), which is incorporated herein by reference. The Company will use the Presentation in various meetings with securities analysts, investors, and others beginning January 11, 2021.

Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated into, Items 2.02 and 7.01, including the Presentation attached hereto as Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits



Exhibit
  No.       Description

99.1          Presentation dated January 2021

104         Cover Page Interactive Data File (embedded with the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses